( "Skip")
Cummins, Cyberonics' Chairman and Chief Executive Officer, will make the
presentation.

We
expect to release the results for Q4 and fiscal 2005 along with guidance for
FY06 and our revised 5 year business outlook in June 2005.com .

conditions headache

(Nasdaq: CYBX)
today announced that senior management will be presenting at the Smith Barney
Citigroup 2005 Small + Mid-Cap Conference on Thursday, February 17, 2005 at
9:25 AM PST at The Four Seasons Hotel in Las Vegas. The
replay of the webcast will be available for 30 days following the
presentation. For additional information please visit us at
http://www.com . Stimulation is delivered by the VNS Therapy
System(TM), an implantable generator similar to a cardiac pacemaker. Epilepsy
is the second most prevalent neurological disorder.
VNS Therapy is at various levels of investigational clinical study as a
potential treatment for anxiety disorders, Alzheimer's disease, chronic
headache/migraine and bulimia.cyberonics.

health headache

Cyberonics will be
presenting at several conferences over the next few months, including the
Citigroup Small and Midcap conference, the SG Cowen conference in Boston in
March and the Morgan Stanley small cap conference in New York in June."
Presentation slides for the Smith Barney Citigroup Conference will be
available on-line at http://www.com/webcasts/sbcitigroup/smc05/33203107.cfm or by going to
http://www.

ABOUT VNS THERAPY AND CYBERONICS
Cyberonics, Inc. was founded in 1987 to design, develop and market medical
devices for the long-term treatment of epilepsy and other chronic neurological
disorders using a unique therapy, vagus nerve stimulation (VNS).
Epilepsy is the second most prevalent neurological disorder. The VNS Therapy System is also
approved for sale as a treatment for epilepsy in all the member countries of
the European Economic Area, Canada, Australia and other markets.

Cyberonics Participating in Piper Jaffray New York Medtech Summit on December 2 2005; Slide Presentation Now Available On Line

" As part of FDA's approval order, Cyberonics is
required to conduct a 450-patient post-market dosing study and a
1,000-patient, five-year patient outcome registry.

migraine headache

Presentation and Audio Webcast Available On-Line

HOUSTON, Cyberonics , Inc. Pamela B. Smith Barney Citigroup will host a webcast of the
presentation live and by replay at
http://www.veracast.com and clicking on the link for this webcast. The VNS Therapy System delivers preprogrammed intermittent
mild electrical pulses to the vagus nerve 24 hours a day.cyberonics.

diseases migraine

Pamela B.cyberonics. The Company's
initial market is epilepsy, which is characterized by recurrent seizures. To date,
more than 28,000 epilepsy patients in 24 countries have accumulated over
79 ,000 patient years of experience using VNS Therapy. The VNS
Therapy System delivers preprogrammed intermittent mild electrical pulses to
the vagus nerve in the patient's neck 24 hours a day. The Company's initial
market was epilepsy, a disorder characterized by recurrent seizures.
The VNS Therapy System was approved by the FDA on July 15, 2005 "as an
adjunctive long-term treatment for chronic or recurrent depression for
patients 18 years of age and older who are experiencing a major depressive
episode and have not had an adequate response to four or more adequate
antidepressant treatments.com or call 1-877-NOW 4 VNS.

diseases neurological

Robert P. Westbrook, Vice President Finance and Administration
and Chief Financial Officer will be available for Q+A.com beginning Thursday, February
17, 2005 at 8:00 AM EST.cyberonics.cyberonics.

Westbrook, Vice President, Finance and
Administration and Chief Financial Officer, will be participating in the Piper
Jaffray New York Medtech Summit at the Essex House Hotel in New York City on
December 2, 2005. Presentation slides are now available on line at
http://www.cyberonics. (Nasdaq: CYBX) was founded in 1987 to design , develop and
market medical devices for the long-term treatment of epilepsy, depression and
other chronic treatment-resistant disorders using a unique therapy, vagus
nerve stimulation (VNS).com or
http://www.vnstherapy.

shopping conditions

Cyberonics Presenting at Smith Barney Citigroup 2005 Small + Mid-Cap Conference on February 17 2005

The Cyberonics
VNS Therapy System was approved by the FDA on July 16, 1997 for use as an
adjunctive therapy in reducing the frequency of seizures in adults and
adolescents over 12 years of age with partial onset seizures that are
refractory to antiepileptic medications . The VNS Therapy System
is approved for sale in the European Economic Area and in Canada as a
treatment for depression in patients with treatment-resistant or treatment-
intolerant major depressive episodes including unipolar depression and bipolar
disorder (manic depression). VNS Therapy is at various levels of
investigational clinical study as a potential treatment for depression,
anxiety disorders , Alzheimer's disease, and chronic headache/migraine. The
Company is headquartered in Houston, Texas and has an office in Brussels,
Belgium. HOUSTON, Cyberonics, Inc. (Nasdaq: CYBX)
today announced that Robert P. ("Skip") Cummins, Cyberonics' Chairman and
Chief Executive Officer, and Pamela B.

The VNS Therapy System is also
approved for sale as a treatment for epilepsy in all the European Economic
Area, Canada, Australia and other markets. To date, more than 32,000 epilepsy
patients in 24 countries have accumulated over 94,000 patient years of
experience using VNS Therapy.
The VNS Therapy System has been approved for sale in the European Economic
Area and in Canada as a treatment for depression in patients with
treatment-resistant or treatment-intolerant major depressive episodes,
including unipolar depression and bipolar disorder (manic depression) since
2001.

shopping conditions

Westbrook , Vice President of Finance and Administration and
Chief Financial Officer commented, "We expect that the FDA approvable decision
of our TRD Expedited Review PMA-Supplement and Amendment that we received last
week will ultimately transform Cyberonics and the entire neuromodulation
industry. We intend to provide ample opportunities for investors and analysts
to interact with Cyberonics senior management over the next few months to
promote well-informed investment decisions going forward. Immediately
following that release, we plan to host a Cyberonics and Neuromodulation
investor and analyst day at Cyberonics headquarters in Houston. Access to the webcast and webcast replay is not protected by a
password. Stimulation
is delivered by the VNS Therapy System, an implantable generator similar to a
cardiac pacemaker.com .

ABOUT VNS THERAPY AND CYBERONICS
Cyberonics, Inc.

The Cyberonics VNS
Therapy System was approved by the FDA on July 16, 1997 for use as an
adjunctive therapy in reducing the frequency of seizures in adults and
adolescents over 12 years of age with partial onset seizures that are
refractory to antiepileptic medications. For more information on
VNS Therapy for treatment-resistant depression, including the
contraindications, warnings and precautions, see the Physician's and Patient's
Manuals and other information at http://www. The Company is headquartered in Houston, Texas
and has an office in Brussels, Belgium. For additional information please
visit us at http://www.

neurological conditions

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)